GW Pharmaceuticals could be on the verge of major growth

361 0

Analysts suggest the cannabis company is in line to see huge gains this year

Not so long ago, investing in the cannabis stock market carried a little cloud along with the trade, some funny parts, and some scary parts. Early on, the cannabis stock market was a bit like a rollercoaster ride going up and down, and sometimes a little sideways. But, still, some investors made a lot of money on cannabis stocks. There’s a particular company linked to the cannabis industry that is expected to have a breakout, and analysts are getting behind it. GW Pharmaceuticals might deserve some investment attention.

GW Pharmaceuticals has flown under the radar until now, but is primed and ready for growth.
The company develops medications based on cannabis and, although it currently has only one major product on the market, that one is selling very well. It is called Epidiolex, which has been found to be effective in treating a rare form of childhood epilepsy. In the last quarter of last year, GW’s sales were up over $130 million, mostly due to Epidiolex.

Some of these companies, especially those in Canada, are simply huge, with grow facilities covering 64 football fields, and being only one of several owned and operated by the company. The “trick” is these days to find the sleepers in the cannabis industry. Small companies that are set to grow exponentially via mergers and state-wide legalizations. Some companies are poised and ready to go if federal legalization ever passes the US congress.

That legalization, once just a pipe dream, is going to happen at some point. 15 states plus the District of Columbia have all legalized recreational cannabis in recent years, and many more are expected to follow suit this year.